Skip to main content
SpringerLink
Log in

Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost

  • Progress in Hematology
  • Recent Advances in Biology and Treatment of Multiple Myeloma
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

This article presents a practical overview of the treatment of younger, newly diagnosed multiple myeloma patients, focusing on novel treatment strategies. With the introduction of effective new agents, multiple myeloma is one of the most active and changing fields in clinical oncology. In addition, monitoring technology has become reliable and practical. Achieving and sustaining minimal residual disease negativity (MRD– ), such as multiparameter flow cytometry (MFC) < 10−5, is one of the goals of therapy. MRD–  is significantly associated with prolonged progression-free survival, whereas MRD persistence (MRD +) is an independent factor for poor progression-free survival. Evidence from several recent studies evaluating modern therapy has further supported the positive correlation between depth of response and outcomes. Multiple myeloma can become a chronic illness with sustained MRD– in a significant number of patients. Our ultimate hope is to leverage tumoricidal-immunomodulatory sequential therapies and to cure a subset of our patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Suzuki K. Current therapeutic strategy for Multiple myeloma. J Clin Oncol. 2013;43:116–24.

    Google Scholar 

  2. Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia–an Asian Myeloma Network study. Am J Hematol. 2014;89:751–6.

    Article  CAS  PubMed  Google Scholar 

  3. Barlogie B. Toward a cure for multiple myeloma? N Engl J Med. 1991;325:1304–6.

    Article  CAS  PubMed  Google Scholar 

  4. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Katodritou E, Papadaki S, Konstantinidou P, Terpos E. Is it possible to cure myeloma without allogeneic transplantation? Transfus Apheres Sci. 2016;54:63–70.

    Article  Google Scholar 

  6. Davies FE. Is molecular remission the goal of multiple myeloma therapy? ASH Educ Book. 2017;1:205–11.

    Google Scholar 

  7. Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma—an IMWG Research Project. Blood Cancer J. 2018;8:123–30.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ravi P, Shaji K, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26–33.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Choudhry P, Galligan D, Wiita AP. Seeking convergence and cure with new myeloma therapies. Trends Cancer. 2018;4:567–82.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–27.

    Article  CAS  PubMed  Google Scholar 

  11. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. IFM 2009 Study: Lenalidomide, Bortezomib, and Dexamethasone with transplantation for Myeloma. N Engl J Med. 2017;376:1311–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Miyazaki K, Suzuki K. Poor mobilizer and its countermeasures. Transfus Apher Sci. 2018;57:623–7.

    Article  PubMed  Google Scholar 

  13. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4:343–50.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, et al. National Cancer Research Institute Haemato-oncology Clinical Studies Group: the effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:340–51.

    Article  Google Scholar 

  15. Botta et al. Best of ASH. Monday, December 3, 2018 San Diego, Blood Cancer in press 2018.

  16. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–19.

    Article  CAS  PubMed  Google Scholar 

  17. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.

    Article  CAS  PubMed  Google Scholar 

  18. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.

    Article  CAS  PubMed  Google Scholar 

  19. Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, et al. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer J. 2018;8:41.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129:3294–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mikhael J, Richardson PG, Usmani SZ, Raje N, Bensinger W, Karanes C, et al. A phase 1b study of Isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019;134:123–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728–34.

    Article  CAS  PubMed  Google Scholar 

  23. Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W): interim analysis results of a randomized, phase 3 study. Lancet Oncol. 2018;19:953–64.

    Article  CAS  PubMed  Google Scholar 

  24. Suzuki K, Ri M, Chou T, Sugiura I, Takezako N, Sunami K, et al. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: a phase 1 study in Japan. Cancer Sci. 2017;108:461–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, et al. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia. 2020;34:180–95.

    Article  CAS  PubMed  Google Scholar 

  26. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–31.

    Article  CAS  PubMed  Google Scholar 

  27. Suzuki K, Sunami K, Ohashi K, Iida S, Mori T, Handa H, et al. Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis. Blood Cancer J. 2017;7:e540.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018;124:4032–43.

    Article  CAS  PubMed  Google Scholar 

  29. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018;379:1811–22.

    Article  CAS  PubMed  Google Scholar 

  30. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2017;374:1621–34.

    Article  CAS  Google Scholar 

  31. Suzuki K, Handa H, Chou T, Ishizawa K, Takubo T, Kase Y, et al. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol. 2017;105:445–52.

    Article  CAS  PubMed  Google Scholar 

  32. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2019;393:253–64.

    Article  CAS  PubMed  Google Scholar 

  33. Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130:2610–8.

    Article  CAS  PubMed  Google Scholar 

  34. Suzuki K, Matsue K, Sunami K. Pomalidomide + Bortezomib + Low-Dose Dexamethasone (PVd) in Japanese Patients Enrolled in OPTIMISMM. In: The 81th annual meeting of the JSH. 2019; OS1-70-4.

  35. Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018;132:2555–633.

    Article  CAS  PubMed  Google Scholar 

  36. Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–66.

    Article  CAS  PubMed  Google Scholar 

  38. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomized, open-label, phase 3 study. Lancet. 2019;10192:29–38.

    Article  Google Scholar 

  39. Peter MV, Cesar R, Brandi R, Nitya N, Luciano JC, Yana L, et al. Efficacy and updated safety analysis of a safety run-in cohort from griffin, a phase 2 randomized study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT). Blood. 2018;132:151.

    Article  Google Scholar 

  40. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 2018;93:179–86.

    Article  CAS  PubMed  Google Scholar 

  42. Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant. 2016;51:492–500.

    Article  CAS  PubMed  Google Scholar 

  43. Kawamura K, Tsukada N, Kanda Y, Ishida T, Suzuki K, Ikeda T, et al. The role of allogeneic transplantation for multiple myeloma in the era of novel agents: a study from the Japanese Society of Myeloma. Biol Blood Marrow Transplant. 2018;24:1392–8.

    Article  PubMed  Google Scholar 

  44. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170–80.

    Article  CAS  PubMed  Google Scholar 

  45. Johnsrud AJ, Johnsrud JJ, Susanibar SA, Kamimoto JJ, Kothari A, Burgess M, et al. Infectious and immunological sequelae of daratumumab in multiple myeloma. Br J Haematol. 2019;185:187–9.

    Article  PubMed  Google Scholar 

  46. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87:935–43.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Affairs (Project Hope). 2013;32:1143–52.

    Article  Google Scholar 

  48. Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, et al. Cost-effectiveness of lenalidomide plus dexamethasone versus bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly diagnosed multiple myeloma. J Med Econ. 2016;19:243–58.

    Article  CAS  PubMed  Google Scholar 

  49. MacEwan JP, Batt K, Yin W, Peneva D, Sison S, Vine S, et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leuk Lymphoma. 2018;59:941–9.

    Article  PubMed  Google Scholar 

  50. Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31:1915–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Director of Myeloma and Amyloidosis Center, Japanese Red Cross Medical Center, Shibuya-ku, Hiroo 4-1-22, Tokyo, Japan

    Kenshi Suzuki

Authors
  1. Kenshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenshi Suzuki.

Ethics declarations

Conflict of interest

K. Suzuki received honoraria from Celgene, Takeda, ONO, Amgen, Novartis, Sanofi, Bristol-Myers Squibb, AbbVie and Janssen, and consulted for Amgen, Janssen, Takeda, and Celgene; received research funding from Bristol-Myers Squibb, Celgene and Amgen.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, K. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. Int J Hematol 111, 512–518 (2020). https://doi.org/10.1007/s12185-020-02841-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02841-w

Keywords

Search

Navigation